About Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals is a company based in Buffalo (United States) founded in 2014. It operates as a HealthTech. Hemogenyx Pharmaceuticals has raised $1 million across 8 funding rounds from investors including Prevail Partners, MINT Capital and 43North. The company has 22 employees as of December 31, 2024. Hemogenyx Pharmaceuticals offers products and services including Breakthrough Therapies. Hemogenyx Pharmaceuticals operates in a competitive market with competitors including Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
- Headquarter Buffalo, United States
- Employees 22 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Hemogenyx Pharmaceuticals Plc
-
Annual Revenue
Not available
-
Net Profit
-$7.04 M (USD)16.01as on Dec 31, 2024
-
EBITDA
-$6.38 M (USD)-3.55as on Dec 31, 2024
-
Total Equity Funding
$1 M (USD)
in 8 rounds
-
Latest Funding Round
$3.41 M (USD), Post-IPO
Feb 10, 2026
-
Investors
Prevail Partners
& 2 more
-
Employee Count
22
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals is a publicly listed company on the LSE with ticker symbol HEMO in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals offers a comprehensive portfolio of products and services, including Breakthrough Therapies.
Therapies are developed for blood diseases and infections.
People of Hemogenyx Pharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals has successfully raised a total of $1M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $3.41 million completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Prevail Partners, MINT Capital and 43North.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Limited information is provided about Prevail Partners' activities.
|
Locked | Locked | Locked | |
|
Seed-stage investments are targeted by 43North in startups.
|
Locked | Locked | Locked | |
|
Offers secure software solutions for building platforms to clients.
|
Locked | Locked | Locked |
Investor details for Hemogenyx Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hemogenyx Pharmaceuticals
Investment portfolio details for Hemogenyx Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Hemogenyx Pharmaceuticals
Detailed financials for Hemogenyx Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hemogenyx Pharmaceuticals Comparisons
Peer comparison for Hemogenyx Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| Locked | Locked | Locked |
Targeted therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
Detailed competitors of Hemogenyx Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hemogenyx Pharmaceuticals
Complete news archive for Hemogenyx Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals was founded in 2014.
Hemogenyx Pharmaceuticals is headquartered in Buffalo, United States. It is registered at Buffalo, New York, United States.
Hemogenyx Pharmaceuticals is a funded company, having raised a total of $1M across 8 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Hemogenyx Pharmaceuticals is 22.
Hemogenyx Pharmaceuticals is focused on the development of innovative therapies for the treatment of life-threatening blood diseases and viral infections. Research and solutions are targeted at addressing critical medical needs in the healthcare sector, particularly in biotechnology. The company operates with facilities in both the United Kingdom and the United States to advance its pipeline of therapeutic products.
Hemogenyx Pharmaceuticals's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and argenx.
Hemogenyx Pharmaceuticals offers Breakthrough Therapies.
Yes, Hemogenyx Pharmaceuticals is publicly traded on LSE under the ticker symbol HEMO.
Hemogenyx Pharmaceuticals has 3 investors. Key investors include Prevail Partners, MINT Capital, and 43North.
The ticker symbol of Hemogenyx Pharmaceuticals is HEMO on LSE.